AL

Ashish Laxman Nagare

Director DIN 03625821
DIN 03625821 First appointment Oct 2011
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since Oct 2011
Shareholding value β€’β€’β€’β€’ Premium profile

About Ashish Laxman Nagare

Data last updated:

Ashish Laxman Nagare was a Director at Sukhakarta Super Speciality Hospital Private Limited (from 2011) and Director at Hirkani Pharmaceuticals Private Limited (from 2017).

DIN 03625821
First Appointment 12 Oct 2011
Oldest Company Age 15 yrs

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director12 Oct 20112011Strike Off
Director15 May 20172017Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Sukhakarta Super Speciality Hospital Private Limited
Hirkani Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Ashish Laxman Nagare

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ashish Laxman Nagare

Ashish Laxman Nagare was first appointed on 12 Oct 2011 as Director at Sukhakarta Super Speciality Hospital Private Limited. The most recent appointment on record is 15 May 2017 at Hirkani Pharmaceuticals Private Limited.

Ashish Laxman Nagare held 2 earlier board appointments: Sukhakarta Super Speciality Hospital Private Limited (Director, from 12 Oct 2011); Hirkani Pharmaceuticals Private Limited (Director, from 15 May 2017).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available